Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001628280-25-017927
Filing Date
2025-04-16
Accepted
2025-04-16 07:46:46
Documents
23
Period of Report
2025-04-16

Document Format Files

Seq Description Document Type Size
1 PRE 14A cccc-20250416.htm   iXBRL PRE 14A 886988
3 cccc-20250416_g1.jpg GRAPHIC 50977
4 cccc-20250416_g2.jpg GRAPHIC 3825
5 cccc-20250416_g3.jpg GRAPHIC 2886
6 cccc-20250416_g4.jpg GRAPHIC 2218
7 cccc-20250416_g5.jpg GRAPHIC 44840
8 cccc-20250416_g6.jpg GRAPHIC 44330
9 cccc-20250416_g7.jpg GRAPHIC 103267
10 cccc-20250416_g8.jpg GRAPHIC 94175
11 cccc-20250416_g9.jpg GRAPHIC 25403
  Complete submission text file 0001628280-25-017927.txt   2414807

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cccc-20250416.xsd EX-101.SCH 928
25 EXTRACTED XBRL INSTANCE DOCUMENT cccc-20250416_htm.xml XML 127152
Mailing Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472 (617) 231-0700
C4 Therapeutics, Inc. (Filer) CIK: 0001662579 (see all company filings)

EIN.: 475617627 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-39567 | Film No.: 25841241
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)